About Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions
What is Protalix Biotherapeutics' stock symbol?
Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."
How were Protalix Biotherapeutics' earnings last quarter?
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.03. The firm earned $4.55 million during the quarter, compared to analyst estimates of $4.40 million. During the same period last year, the business earned ($0.48) EPS. View Protalix Biotherapeutics' Earnings History.
What price target have analysts set for PLX?
1 equities research analysts have issued 12 month price targets for Protalix Biotherapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $5.00 in the next year. View Analyst Ratings for Protalix Biotherapeutics.
Are investors shorting Protalix Biotherapeutics?
Protalix Biotherapeutics saw a drop in short interest in May. As of May 31st, there was short interest totalling 5,081,891 shares, a drop of 3.1% from the May 15th total of 5,242,949 shares. Based on an average trading volume of 416,075 shares, the short-interest ratio is presently 12.2 days. Approximately 3.7% of the company's shares are sold short.
Who are some of Protalix Biotherapeutics' key competitors?
Some companies that are related to Protalix Biotherapeutics include Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Neptune Technologies & Bioressources (NEPT) and Monash IVF Group (MVF).
Who are Protalix Biotherapeutics' key executives?
Protalix Biotherapeutics' management team includes the folowing people:
- Mr. Moshe Manor, Chief Exec. Officer, Pres and Director (Age 62)
- Dr. Yoseph Shaaltiel Ph.D., Founder and Exec. VP of R&D (Age 64)
- Mr. Yossi Maimon CPA, MBA, Chief Financial Officer, VP, Treasurer and Sec. (Age 47)
- Mr. Tzvi Palash M.Sc., B.Sc., Chief Operating Officer (Age 61)
- Dr. Einat Brill-Almon Ph.D., Sr. VP of Product Devel. (Age 58)
Has Protalix Biotherapeutics been receiving favorable news coverage?
Media headlines about PLX stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Protalix Biotherapeutics earned a news impact score of 0.08 on Accern's scale. They also assigned headlines about the company an impact score of 47.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Protalix Biotherapeutics' major shareholders?
Protalix Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (2.24%) and SG Americas Securities LLC (0.15%). Company insiders that own Protalix Biotherapeutics stock include Camber Capital Management Llc, Madalena Energy Inc, Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Institutional Ownership Trends for Protalix Biotherapeutics.
Which institutional investors are buying Protalix Biotherapeutics stock?
PLX stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc. and SG Americas Securities LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Insider Buying and Selling for Protalix Biotherapeutics.
How do I buy shares of Protalix Biotherapeutics?
Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalix Biotherapeutics' stock price today?
One share of PLX stock can currently be purchased for approximately $0.44.
How big of a company is Protalix Biotherapeutics?
Protalix Biotherapeutics has a market capitalization of $308.37 million.
How can I contact Protalix Biotherapeutics?
Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.
MarketBeat Community Rating for Protalix Biotherapeutics (PLX)MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days.